Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dna X (SONM) Net Margin (2018 - 2025)

Dna X (SONM) has disclosed Net Margin for 8 consecutive years, with 29.31% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Margin fell 1259.0% year-over-year to 29.31%, compared with a TTM value of 50.97% through Sep 2025, down 2738.0%, and an annual FY2024 reading of 58.83%, down 5873.0% over the prior year.
  • Net Margin was 29.31% for Q3 2025 at Dna X, up from 66.8% in the prior quarter.
  • Across five years, Net Margin topped out at 53.25% in Q4 2022 and bottomed at 98.31% in Q4 2024.
  • Average Net Margin over 5 years is 32.32%, with a median of 29.31% recorded in 2025.
  • The sharpest move saw Net Margin skyrocketed 12695bps in 2022, then plummeted -8824bps in 2024.
  • Year by year, Net Margin stood at 73.7% in 2021, then soared by 172bps to 53.25% in 2022, then tumbled by -119bps to 10.07% in 2023, then crashed by -876bps to 98.31% in 2024, then surged by 70bps to 29.31% in 2025.
  • Business Quant data shows Net Margin for SONM at 29.31% in Q3 2025, 66.8% in Q2 2025, and 2.74% in Q1 2025.